CIN-107 for Hypertension

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
CinCor Site 1, Lake Worth, FL
Hypertension
CIN-107 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have completed Part 1 or Part 2 of Study CIN-107-124. The study will be conducted at clinical sites that have participated in the double-blind, Phase 2 Study CIN-107-124.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Hypertension

Study Objectives

24 Primary · 5 Secondary · Reporting Duration: 1 year

1 year
Body temperature
Body weight
Change from baseline on diastolic blood pressure (DBP)
Change from baseline on standing systolic blood pressure (SBP)
Electrocardiograms (ECGs) - Heart rate
Electrocardiograms (ECGs) - QRS interval
Electrocardiograms (ECGs) - QT interval
Electrocardiograms (ECGs) - QTc (QTcF)
Electrocardiograms (ECGs) - RR interval
Heart rate
Mean diastolic blood pressure (DBP) change
Mean systolic blood pressure (SBP) change
Number of participants with abnormal hematology lab test results, if appropriate.
Number of participants with abnormal laboratory standard safety chemistry panel test results, if appropriate.
Number pf participants with abnormal laboratory coagulation test results, if appropriate
Number pf participants with abnormal laboratory electrolyte imbalance test results, if appropriate
Number pf participants with abnormal urinalysis, if appropriate
Percentage of non-responders in Study CIN-107-124 achieving a seated SBP response <130 mmHg with CIN-107
Percentage of patients achieving a seated SBP <130 mmHg
Percentage of patients requiring down-titration of CIN-107
Percentage of patients requiring rescue medication
Percentage of patients resuming a single background antihypertensive agent
Percentage of responders in Study CIN-107-124 maintaining a seated SBP response <130 mmHg with CIN-107
Respiratory rate
Standing blood pressure (BP)
TEAEs leading to premature discontinuation of study drug
TEAEs of special interest
Treatment-emergent adverse events (TEAEs)
Treatment-emergent serious adverse events (SAEs)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Hypertension

Trial Design

1 Treatment Group

Experimental 2 mg CIN-107 tablets QD
1 of 1
Experimental Treatment

200 Total Participants · 1 Treatment Group

Primary Treatment: CIN-107 · No Placebo Group · Phase 2

Experimental 2 mg CIN-107 tablets QD
Drug
Experimental Group · 1 Intervention: CIN-107 · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CIN-107
2019
Completed Phase 2
~470

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
Closest Location: CinCor Site 1 · Lake Worth, FL
Photo of florida 1Photo of florida 2Photo of florida 3
2022First Recorded Clinical Trial
4 TrialsResearching Hypertension
2 CompletedClinical Trials

Who is running the clinical trial?

CinCor Pharma, Inc.Lead Sponsor
7 Previous Clinical Trials
994 Total Patients Enrolled
6 Trials studying Hypertension
976 Patients Enrolled for Hypertension

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have completed the study.
Male patients must agree to abstain from sperm donation from Day 1 through 90 days after the final dose of study drug.
Have had acceptable safety and tolerability during Study CIN-107-124 as determined by the Investigator or Medical Monitor.
You are able and willing to give informed consent for participation in the clinical study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.